The trajectory of companies tied to Sildenafil's history presents a complex investment scenario . While the initial surge generated substantial returns , generic competition have significantly eroded sales . Investing in related pharmaceutical companies now requires a discerning assessment of proprietary protection , evolving patient shifts , and t